LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Smith & Nephew PLC ADR

Cerrado

36.14 1.92

Resumen

Variación precio

24h

Actual

Mínimo

35.86

Máximo

36.16

Métricas clave

By Trading Economics

Ingresos

296M

Ventas

3B

P/B

Media del Sector

31.586

121.746

Rentabilidad por dividendo

2.17

Margen de beneficios

9.895

Empleados

17,000

EBITDA

723M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-4.75% downside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.17%

2.26%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

15B

Apertura anterior

34.22

Cierre anterior

36.14

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Smith & Nephew PLC ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 feb 2026, 23:21 UTC

Adquisiciones, fusiones, absorciones

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 feb 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 feb 2026, 23:40 UTC

Charlas de Mercado

Gold Falls on Possible Position Adjustments -- Market Talk

15 feb 2026, 23:06 UTC

Ganancias

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 feb 2026, 23:04 UTC

Ganancias

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 feb 2026, 23:04 UTC

Ganancias

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Ganancias

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Ganancias

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 feb 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 feb 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 feb 2026, 22:52 UTC

Adquisiciones, fusiones, absorciones

Qube Shareholders to Receive A$5.20/Share in Cash

15 feb 2026, 22:52 UTC

Adquisiciones, fusiones, absorciones

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 feb 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 feb 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 feb 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 feb 2026, 22:14 UTC

Adquisiciones, fusiones, absorciones

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 feb 2026, 22:14 UTC

Adquisiciones, fusiones, absorciones

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 feb 2026, 20:48 UTC

Ganancias

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 feb 2026, 20:47 UTC

Ganancias

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 feb 2026, 20:46 UTC

Ganancias

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 feb 2026, 20:45 UTC

Ganancias

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 feb 2026, 20:44 UTC

Ganancias

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 feb 2026, 20:44 UTC

Ganancias

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 feb 2026, 20:43 UTC

Ganancias

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 feb 2026, 20:42 UTC

Ganancias

BlueScope Net Debt A$2.2 Million at Dec. 31

15 feb 2026, 20:42 UTC

Ganancias

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 feb 2026, 20:41 UTC

Ganancias

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 feb 2026, 20:40 UTC

Ganancias

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 feb 2026, 20:40 UTC

Ganancias

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 feb 2026, 20:39 UTC

Ganancias

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Comparación entre iguales

Cambio de precio

Smith & Nephew PLC ADR previsión

Precio Objetivo

By TipRanks

-4.75% descenso

Estimación a 12 Meses

Media 34.46 USD  -4.75%

Máximo 34.91 USD

Mínimo 34 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Smith & Nephew PLC ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

2 ratings

0

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

26.64 / 28.37Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat